A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis (NASH) participants with Stage 2, Stage 3 liver fibrosis.
This study is designed to assess response to treatment on measures of fibrosis and other efficacy parameters. It will also assess dose response and overall safety.
Inclusion Criteria:
Exclusion Criteria:
- Key Exclusion Criteria
Phoenix, Arizona 85013, United States
Aurora, Colorado 80045, United States
Chicago, Illinois 60612, United States
Baltimore, Maryland 21202, United States
Pittsburgh, Pennsylvania 15213, United States
Fort Sam Houston, Texas 78235-8200, United States
Paris, 75651, France
Kurume, Fukuoka, 830-0011, Japan
Kurume, Fukuoka, 830-0011, Japan
Osaka-Fu, 565-0871, Japan
Osaka-Fu, 565-0871, Japan
Yokohama, Kanagawa, 213-8507, Japan
Yokohama, Kanagawa, 213-8507, Japan
Katowice, 40-752, Poland
Cambridge, CB2 0QQ, United Kingdom
London, SW10 9NH, United Kingdom